Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.42 |
| ▸ | MET | P08581 | 6/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26626311 | 0.92 | TP53 (0.44) | TP53HDAC1MEN1KMT2APTGDR2 | |
| SCHEMBL23297255 | 0.91 | HDAC1 (0.42) | TP53HDAC1MEN1KMT2AMET | |
| SCHEMBL23297322 | 0.90 | MEN1 (0.43) | TP53HDAC1MEN1KMT2AMET | |
| SCHEMBL23297254 | 0.90 | MET (0.48) | TP53MEN1KMT2AMET | |
| SCHEMBL23297285 | 0.90 | PDE4A (0.51) | TP53HDAC1MEN1KMT2AMET | |
| SCHEMBL23297321 | 0.88 | MET (0.52) | MEN1KMT2AMETMAPTSMN1; SMN2 | |
| SCHEMBL29776815 | 0.88 | MET (0.42) | TP53HDAC1MEN1KMT2AMET | |
| SCHEMBL29776817 | 0.88 | MET (0.42) | TP53HDAC1MEN1KMT2AMET | |
| SCHEMBL23559024 | 0.88 | POLB (0.40) | TP53HDAC1MEN1KMT2AMET | |
| SCHEMBL23297312 | 0.88 | MET (0.42) | TP53HDAC1MEN1KMT2AMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12240833-B2 | Pyridazinone compounds and uses thereof | EDGEWISE THERAPEUTICS, INC. (US) | 2025-03-04 | — | — | US | disclosed |
| EP-3877367-B1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS INC (US) | 2024-05-22 | — | — | EP | disclosed |
| US-20230338375-A1 | SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES | EDGEWISE THERAPEUTICS, INC. | 2023-10-26 | — | — | US | disclosed |
| US-20230338375-A1 | SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES | EDGEWISE THERAPEUTICS, INC. | 2023-10-26 | — | — | US | disclosed |
| US-20230048816-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2023-02-16 | — | — | US | disclosed |
| US-20230048816-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2023-02-16 | — | — | US | disclosed |
| US-11390606-B2 | Pyridazinone compounds and uses thereof | EDGEWISE THERAPECUTICS, INC. (US) | 2022-07-19 | — | — | US | disclosed |
| WO-2021231630-A1 | SUBSTITUTED PYRIDAZINONE FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES | EDGEWISE THERAPEUTICS, INC. (US) | 2021-11-18 | — | — | WO | disclosed |
| US-20210130327-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2021-05-06 | — | — | US | disclosed |
| US-20210130327-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230338375-A1 | SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES | IL6, MUSK, SMN1; SMN2 | TP53 4843/4885HDAC1 444/4885MEN1 4467/4885 |
| US-12240833-B2 | Pyridazinone compounds and uses thereof | IL6, IL1B, IL1A | TP53 4800/4885HDAC1 333/4885MEN1 4368/4885 |
| US-11390606-B2 | Pyridazinone compounds and uses thereof | IL6, IL1B, IL1A | TP53 4800/4885HDAC1 333/4885MEN1 4368/4885 |
| US-20210130327-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | IL6, IL1B, IL1A | TP53 4800/4885HDAC1 333/4885MEN1 4368/4885 |
| US-20230048816-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | IL6, IL1B, IL1A | TP53 4800/4885HDAC1 333/4885MEN1 4368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.